Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Safety of 15 vs 60 Minute Ibandronate Infusions in Metastatic Bone Disease
NCT02716792Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibandronic acid in metastatic bone disease (MBD), sponsored by Roche. Started Jan 2006; status: completed.
02
Drugs
ibandronic acid
03
Conditions
metastatic bone disease (MBD)
Beyond the preview
Go deeper on NCT02716792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716792.